| Primary | Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per Day | Participants recorded micturitions in the e-diary during three days. The mean number of micturitions was calculated as the average number of times a participant recorded a micturition per day during the 3-day period. Only voluntary micturitions were counted and the episodes of incontinence were not included. | The analysis population was the full analysis set (FAS), which consisted of all randomized participants who took at least 1 dose of double-blind study drug, reported at least 1 baseline micturition recorded in the 3-day e-diary and at least 1 postbaseline micturition. Last observation carried forward (LOCF) was used for missing values in the EoT. | Posted | | Least Squares Mean | Standard Error | micturitions per day | | Baseline and Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-2.00± 0.13
- OG001-1.62± 0.15
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Placebo vs. Mirabegron: Differences of adjusted change from baseline values as well as the 95% CIs were generated from the ANCOVA model with treatment group, age group (<65, >=65 years) and geographical region as fixed factors and baseline value as a covariate. | ANCOVA | | 0.039 | | Least Squares (LS) Mean of Difference | -0.39 | Standard Error of the Mean | 0.19 | 2-Sided | 95 | -0.76 | -0.02 | | | | | Superiority | | |
|
| Secondary | Change From Baseline to Week 4, Week 8, and Week 12 in Mean Number of Micturitions Per Day | Participants recorded micturitions in the e-diary during three days. The mean number of micturitions was calculated as the average number of times a participant recorded a micturition per day during the 3-day period. Only voluntary micturitions were counted and the episodes of incontinence were not included. | The analysis population was the FAS. | Posted | | Least Squares Mean | Standard Error | micturitions per day | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Volume Voided Per Micturition | The mean volume voided per micturition during 3 days of the 3-day micturition diary period. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | mL per micturition | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Incontinence Episodes Per Day | An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated as the average number of times a participant recorded an incontinence episode per day during the 3-day micturition diary period. | The analysis population was the full analysis set - incontinence (FAS-I), which consisted of all randomized participants who took at least 1 dose of double-blind study drug and reported 1 micturition at baseline and postbaseline in the 3-day e-diary. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | incontinence episodes per day | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per Day | Urgency was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. An urgency episode was defined as any micturition or incontinence episode with a severity of grade 3 or 4, assessed by participants based on the Patient Perception of Intensity of Urgency Scale (PPIUS), where 0 = No urgency; 1 = Mild urgency; 2 = Moderate urgency, could delay voiding a short while; 3 = Severe urgency, could not delay voiding; 4 = Urge incontinence, leaked before arriving to the toilet. The mean number of urgency episodes (grade 3 and/or 4) per day was calculated as the average number of times a participant recorded an urgency episode (grade 3 and/or 4) with or without incontinence per day during the 3-day micturition diary period. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | urgency episodes per day | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
|
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in International Prostate Symptom Score (IPSS) Total Score | The International Prostate Symptom Score (IPSS) consists of 7 questions concerning urinary symptoms and 1 question concerning quality of life (QoL) with total score and subscores (voiding, storage and QoL). The IPSS total score classification ranges from mild (0 to 7) to moderate (8 to 19) or severe (20 to 35). Higher IPSS scored indicated more severe symptoms. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in IPSS Subscale Voiding Score | The International Prostate Symptom Score (IPSS) consists of 7 questions concerning urinary symptoms and 1 question concerning quality of life (QoL) with total score and subscores (voiding, storage and QoL). Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The subscale voiding score is the sum of the responses to 4 voiding symptoms questions (incomplete emptying, intermittency, weak stream, and straining). The lowest and highest possible scores range from 0 to 20 (mildly symptomatic to severely symptomatic). A higher score is indicative of worse condition and a negative change from baseline indicates an improvement. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12, and EoT in IPSS Subscale Storage Score | The International Prostate Symptom Score (IPSS) consists of 7 questions concerning urinary symptoms and 1 question concerning quality of life (QoL) with total score and subscores (voiding, storage and QoL). Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The subscale storage score is the sum of the responses to 3 storage symptoms questions (frequency, urgency, and nocturia). The lowest and highest possible scores range from 0 to 15 (mildly symptomatic to severely symptomatic). A higher score is indicative of worse condition and a negative change from baseline indicates an improvement. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in IPSS Subscale Quality of Life (QoL) Score | The International Prostate Symptom Score (IPSS) consists of 7 questions concerning urinary symptoms and 1 question concerning quality of life (QoL) with total score and subscores (voiding, storage and QoL). The QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The lowest and highest possible score ranges from 0 to 6 (very pleased to terrible). A higher score is indicative of worse condition and a negative change from baseline indicates an improvement. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Urgency Incontinence Episodes Per Day | Urgency Incontinence was defined as the complaint of involuntary leakage accompanied by or immediately proceeded by urgency. The mean number of urgency incontinence episodes was calculated as the average number of times a participant recorded an urgency incontinence episode per day during the 3-day micturition diary period. | The analysis population was the FAS-I. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | urgency incontinence episodes per day | | Baseline and Weeks 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Symptom Bother Score | Overactive bladder symptoms were assessed using the Symptom Bother Scale of the Overactive Bladder questionnaire (OAB-q). The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 questions, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). Lower scores on OAB-q symptom bother indicate a better response. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Total Health Related Quality of Life (HRQL) Score | The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A higher score on OAB-q HRQL indicated a better response. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Coping Score | The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQL). The HRQL portion consists of 25 HRQL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. A higher score on OAB-q HRQL indicated a better response. The lowest and highest possible scores for the Coping subscale ranges from 8 to 48. The Coping score was calculated by adding the 8 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Concern Score | The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQL). The HRQL portion consists of 25 HRQL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. A higher score on OAB-q HRQL indicated a better response. The lowest and highest possible scores for the Concern subscale ranges from 7 to 42. The Concern score was calculated by adding the 7 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Sleep Score | The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQL). The HRQL portion consists of 25 HRQL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. A higher score on OAB-q HRQL indicated a better response. The lowest and highest possible scores for the Sleep subscale ranges from 5 to 30. The Sleep score was calculated by adding the 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in HRQL Subscale Social Interaction Score | The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQL). The HRQL portion consists of 25 HRQL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. A higher score on OAB-q HRQL indicated a better response. The lowest and highest possible scores for the Social Interaction subscale ranges from 5 to 30. The Social Interaction score was calculated by adding the 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in European Quality of Life in 5 Dimensions and 5 Levels (EQ-5D-5L Questionnaire) Utilities | The EQ-5D-5L is an international standardized non-disease specific generic instrument for describing and valuing health status. It has a multidimensional measure of health-related QoL, capable of being expressed as a single index value and specifically designed to complement other health status measures. The EQ-5D-5L has five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response levels (e.g., 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems/unable to perform the activity). Health-state utility (HSU) data are estimates of the preference for a given state of health on a cardinal numeric scale, where a value of 1.0 represents full health, 0.0 represents dead, and negative values represent states worse than death. Missing EoT values were imputed using LOCF method. | The analysis population was the FAS. | Posted | | Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
|
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Patient Perception of Bladder Condition (PPBC) | The PPBC is a validated, global assessment tool using a 6-point Likert scale that asks participants to rate their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems. A higher score indicated a worse perception of bladder condition. | The analysis population was the FAS. Missing values in the EoT were imputed using the LOCF method. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Total Urgency and Frequency Score (TUFS) | The TUFS was calculated by adding the PPIUS scores of every void in a participant's 3-day diary, and dividing this by the number of days recorded in the diary. Due to a programming failure in the e-diary data for the number of pads used was not collected. | The analysis population was the FAS. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8 and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
| |
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours | A nocturia episode was defined as waking at night one or more time to void (i.e., any voiding associated with sleep disturbance between the date/time the participant goes to bed with the intention to sleep until the date/time the participant gets up in the morning with the intention to stay awake). A night time episode of incontinence is not considered a nocturia episode. The mean number of nocturia episodes per day (24 hours) was calculated as the average number of times a participant recorded a nocturia episode per day during the 3-day micturition diary period. | The analysis population was the full analysis set - nocturia (FAS-N), which consisted of all randomized participants who took at least 1 dose of double-blind study drug and reported 1 micturition at baseline and postbaseline in the 3-day e-diary. | Posted | | Least Squares Mean | Standard Error | nocturia episodes per 24 hours | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study. | | OG001 | Placebo | Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study. |
|
| Secondary | Change From Baseline to Week 4, Week 8, Week 12 and EoT in Treatment Satisfaction Visual Analog Scale (TS-VAS) | The TS-VAS is a visual analog scale that asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) to 100 (Yes, completely). | The analysis population consisted of the FAS. LOCF was used for EOT. | Posted | | Least Squares Mean | Standard Error | units on a scale | | Baseline and Weeks 4, 8, and 12 | | | | ID | Title | Description |
|---|
| OG000 | Mirabegron | Participants received mirabegron at an initial dose of 25 mg, mirabegron was increased to 50 mg after 4 weeks. Participants continued once daily treatment with tamsulosin hydrochloride 0.4 mg throughout the study. | | OG001 | Placebo | Participants received placebo to match mirabegron at an initial dose of 25 mg, placebo to match mirabegron was increased to 50 mg after 4 weeks. Participants continued once daily treatment with tamsulosin hydrochloride 0.4 mg throughout the study. |
| |